

South Carolina
Department of Health and Human Services
Post Office Box 8206
Columbia, South Carolina 29202-8206

Pharmacy and Therapeutics (P&T) Committee Meeting
November 7, 2007
MINUTES

1. Call To Order

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, November 7, 2007.

2. Welcome

Debbie Tapley, R.Ph., Vice-Chair of the P&T Committee, called the meeting to order and welcomed members, guests, and staff members.

Debbie Tapley announced that the Chair of the P&T Committee, Dr. Robin LaCroix has resigned from the P&T committee.

Debbie Tapley opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

3. Committee Members Present:

Ed Behling, M.D.

Kelly Jones, Pharm.D.

Thomas Phillips, R.Ph.

Greg Browning, M.D.

Jim Lindsay, M.D.

Debbie Tapley, R.Ph, MBA

Charmaine George, M.D.

Sara Lindsey, M.D.

George E. Vess, Pharm. D.

Harry Wright, M.D.

DHHS Staff Present:

Emma Forkner, DHHS Director

Felicity Myers, Deputy Director for Programs

Deirdra Singleton, J.D. Office of General Counsel

Byron Roberts, J.D. Office of General Counsel

James M Assey, R.Ph.

Mike Blakely, R.Ph.

April Smith

Other Representation:

Mary Roberts, R.Ph – First Health

Pharmaceutical Industry Speakers

4. Discussion Topics

A. Committee Meeting Minutes, Wednesday, August 1, 2007.

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

Jim Assey introduced Emma Forkner, the new Director of Medicaid. Mrs. Forkner addressed the committee and provided some of her background information and thanked the committee for their participation.

Mr.Assey also introduced Felicity Meyers, new Deputy Director of Programs and Mike Blakely new team leader for the pharmacy program.

B. Public Comment

The rules for public comment were outlined. Vice Chair Tapley instructed the speakers that presentations would be limited to three minutes. The Committee members' meeting packets included the speakers' curriculum vitae and signed disclosure declaration forms that were submitted prior to the meeting. The following speakers (in order of appearance) discussed the drugs listed below.

Company	Speaker	Drug
Merck	Gary Dietrich, M.D. Senior Region Medical Director, Merck	Januvia®/ Janumet®
Sankyo	Guido H. Ring, M.D. Internal Medicine and Nephrology Crisp Regional Hospital	Azor®
Novartis	Ray Lancaster Scientific Operations, Novartis	Exforge®
Novartis	Ray Lancaster Scientific Operations, Novartis	Tekturna®
Amylin	Sharm Steadman, Pharm.D.,BCPS, FASHP, CDE USC Department of Family and Preventative Medicine	Byetta®
Amylin	Marjan Massuidi, Pharm.D. Managed Care Liaison, Amylin Pharmaceuticals	Symlin®

C. Drug Classes for Review

Mary Roberts, R.Ph., First Health Services Corporation, led the discussion for the following drug classes:

- Increlin Mimetics
- Amylin Analogs
- ARB/CCB Combinations
- Direct Renin Inhibitors
- DPP-4 Inhibitors and Combination Products

The chart below represents the recommendations for the P & T Committee:

NO PA REQUIRED "PREFERRED"	PA REQUIRED
<i>Increlin Mimetics and Amylin Analogs</i>	
BYETTA® SYMLIN®	
<i>Preferred with a step edit to confirm the presence of anti-diabetic agents in history</i>	
<i>ARB/CCB Combination Products</i>	
EXFORGE®	AZOR®
<i>Direct Renin Inhibitors</i>	
TEKTURNA®	
<i>Preferred with a step edit to confirm the presence of an ARB in history</i>	
<i>DPP-4 Inhibitors and Combination Products</i>	
JANUVIA® JANUMET®	
<i>Preferred with a step edit to confirm the presence of anti-diabetic agents in history</i>	

5. **Old Business**

Mary Roberts reviewed program data and aggregate supplemental savings with the committee.

6. **New Business**

Mary Roberts presented a demonstration of the new Web PA application that First Health will be making available to prescribers as a new PA request option.

7. **Resolved Items**

Recommendations regarding PDL status for drugs in the following classes were approved for submission to DHHS.

Increlin Mimetics

Amylin Analogs

ARB/CCB Combinations

Direct Renin Inhibitors

DPP-4 Inhibitors and Combination Products

8. **Closing Comments**

The next meeting will be held on Wednesday, February 6, 2007 at 4:00 p.m. at the same location.

9. **Adjournment**

The meeting adjourned at 6:00 p.m.